WOMAC® 3.1 User Guide XII
The following is the Table of Contents from the WOMAC® 3.1 User Guide XII.
FOREWORD
OVERVIEW
CONCEPTUAL BASIS
DERIVATION OF THE ITEM INVENTORY
VALIDATION STUDIES (RELIABILITY, VALIDITY, RESPONSIVENESS)
Orthopaedic Validation Study
Pharmacologic Validation Study
SPECIFIC CLINIMETRIC ISSUES
Likert vs Visual Analogue Scaling
Prior Score Availability
Time Frame Dependency
Signal vs Aggregate Measurement
Parametric vs Non-Parametric Analysis
Relative Efficiency
Weighting and Aggregation
Alternate Language Translations
Rasch Analyses
Predictive Value
SF-WOMAC
Applications in Studies of Purported Structure-Modifying Drugs in OA
Applications in non-OA disorders
ADMINISTRATIVE ISSUES
Formatting the Index
Index Presentation
Score Calculation
Scale Transformation Issues
Statistical Issues
SCORE INTERPRETATION ISSUES
Responder Criteria
State-attainment Criteria
Population-based Age- and Gender-Specific Normative Values
ELECTRONIC DATA CAPTURE (EDC)
GUIDANCE DOCUMENTS
OMERACT Core Set Measures for OA
OARSI Clinicial Trials Guidelines
IMMPACT Guidelines for Pain Studies
FDA Guidance Document on Patient Reported Outcome Measures
EMA Guidance Document on Clinical Investigation of Medicinal Products in OA
REFERENCES
APPENDICES
Appendix I: WOMAC® Language List
Appendix II: An Explanation Of The Meaning of Questions In The WOMAC® Osteoarthritis
Index Inventory
RELATED OSTEOARTHRITIS PRO MEASURES
Australian/Canadian (AUSCAN™) Osteoarthritis Hand Index
Osteoarthritis Global Index (OGI™)
Osteoarthritis Modular Measurement System (O2MS™)
Return to WOMAC® 3.1 Index
|
|
| | Home | | | Back to top |